Literature DB >> 8352697

Transconjunctival entropion repair.

S C Dresner1, J W Karesh.   

Abstract

Involutional lower-eyelid entropion has three underlying correctable causes: eyelid laxity, overriding of the orbicularis oculi muscle, and attenuation of the lower-eyelid retractors. We describe a new technique for correcting this problem. A transconjunctival approach is used to advance or fortify the lower-eyelid retractors. The orbicularis oculi muscle can also be addressed through this approach. Combining this technique with lateral canthal resuspension anatomically corrects the entropion by addressing all three correctable causes. Transconjunctival blepharoplasty can also be performed in conjunction with this technique. Twenty-three eyelids of 18 patients successfully underwent this procedure. Six patients underwent simultaneous transconjunctival blepharoplasty. Follow-up ranged between 9 and 18 months. There were no postoperative recurrences, overcorrections, or lower-eyelid retraction. This approach yields a stable and definitive repair of involutional entropion with excellent postoperative cosmesis.

Entities:  

Mesh:

Year:  1993        PMID: 8352697     DOI: 10.1001/archopht.1993.01090080140030

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  [Surgical management of entropion].

Authors:  K Wozniak; F Sommer
Journal:  Ophthalmologe       Date:  2010-10       Impact factor: 1.059

2.  A small incision technique for repairing involutional lower eyelid entropion.

Authors:  Hatice Deniz Ilhan; Aylin Yaman; Meltem Soylev Bajin
Journal:  Int Ophthalmol       Date:  2019-10-12       Impact factor: 2.031

3.  Everting suture correction of lower lid involutional entropion.

Authors:  M Wright; D Bell; C Scott; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  1999-09       Impact factor: 4.638

4.  Orbicularis oculi muscle transposition for repairing involutional lower eyelid entropion.

Authors:  Juan Ding; Fengju Chen; Wenjuan Zhai; Hong Zhao; Ye Pan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-20       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.